<DOC>
	<DOCNO>NCT01202955</DOCNO>
	<brief_summary>The goal within-subject pilot study : ( 1 ) ass feasibility safety administer Catechol-O-Methyl-Transferase ( COMT ) inhibitor , tolcapone , smoker , ( 2 ) explore whether tolcapone may reduce abstinence-induced cognitive affective symptom promote relapse . A secondary exploratory goal ass whether effect may pronounce smoker carry high risk COMT genotype smoking relapse : COMT val/val .</brief_summary>
	<brief_title>Pilot Study Tolcapone Smokers</brief_title>
	<detailed_description>Despite decade research develop pharmacotherapies nicotine dependence ( ND ) , current FDA approve medication ( bupropion , varenicline NRTs ) majority ( &gt; 60 % ) smoker relapse first year follow treatment ( Lerman , Patterson et al . 2005 ; Tonstad , Tonnesen et al . 2006 ) . Testing novel medication may reduce abstinence symptom prompt smoke relapse plausible route identify new treatment nicotine dependence . The goal within-subject pilot study : ( 1 ) ass feasibility safety administer Catechol-O-Methyl-Transferase ( COMT ) inhibitor , tolcapone , smoker , ( 2 ) explore whether tolcapone may reduce abstinence-induced cognitive affective symptom promote relapse . A secondary exploratory goal ass whether effect may pronounce smoker carry high risk COMT genotype smoking relapse : COMT val/val . Sixteen smoker ( 8 met/met genotype 8 val/val genotype ) meet study eligibility criterion complete two 10-day medication period : one take tolcapone one take placebo ( order counterbalance ) . The test session occur day 7 medication phase include three computerized task . Participants ask refrain smoking least 14 hour ( overnight ) prior test day medication phase . There 3-day medication taper day 8-10 medication period , follow washout period least 7 day medication period . The main outcome evaluate participant enrollment retention , side effect , performance computerized task . Positive result pilot study would provide basis large scale investigation ass efficacy tolcapone medication ameliorates abstinence induce neurocognitive symptom smoker .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Tolcapone</mesh_term>
	<criteria>1 . Healthy determine responsible physician , base medical evaluation include history , physical psychiatric examination , laboratory test , liver function monitoring . 2 . Smokers 18 55 year age IQ great 90 . 3 . Capable give write informed consent , include compliance requirement restriction , list consent form . 4 . Based upon selfreport , subject must smoke &gt; 10 cigarettes/day interested quit smoke next 6 month ( i.e. , treatmentseekers ) . 5 . Women childbearing potential must consent use medically accept method birth control ( e.g. , condoms spermicide , oral contraceptive , Depoprovera injection , contraceptive patch , tubal ligation ) . Smoking Behavior 1 . Use chew tobacco snuff 2 . Current enrollment plan enroll another smoking cessation program next month 3 . Plan use nicotine substitute smoke cessation treatment next month 4 . Provide baseline carbon monoxide ( CO ) reading &lt; 10ppm Alcohol/Drug Exclusion Criteria 1 . History substance abuse and/or currently receive treatment substance abuse ( e.g. , alcohol , opioids , cocaine , marijuana , MDMA/ecstasy , stimulant ) 2 . Current alcohol consumption exceed &gt; 14 standard drinks/week men &gt; 7 standard drinks/week woman last 6 month Medication Exclusion Criteria 1 . Current use recent discontinuation ( within last 4weeks ) medication include follow : Any form psychotropic medication include : antipsychotic , atypical antipsychotic , moodstabilizers , antidepressant ( tricyclic , SSRI 's , MAOI 's , nonselective MAOIs , Wellbutrin/Zyban ) , antipanic agent , antiobsessive agent , antianxiety agent , stimulant ( e.g. , Provigil , Ritalin ) Varenicline Medication chronic pain Anticoagulants ( e.g. , Warfarin ) Any heart medication Daily medication asthma Apomorphine , dobutamine , isoproterenol , levodopa , methyldopa , sympathomimetic ( e.g. , albuterol , pseudoephedrine ) 2 . Current use smoking cessation medication . Medical Exclusion Criteria 1 . Women pregnant , planning pregnancy , lactate . 2 . History current diagnosis psychosis , major depression bipolar disorder , schizophrenia , Axis 1 disorder identify MINI . 3 . Serious unstable disease within past 6 month ( e.g. , cancer [ except squamous cell carcinoma ] , heart disease , HIV , liver disease , Parkinson 's disease ) . 4 . History epilepsy seizure disorder . 5 . History current diagnosis ( last 6months ) abnormal rhythm and/or tachycardia ( &gt; 100 beats/minute ) ; history current diagnosis chronic obstructive pulmonary disease ( COPD ) , cardiovascular disease ( stroke , angina , coronary heart disease ) , heart attack last 6 month , uncontrolled hypertension ( SBP &gt; 150 DBP &gt; 90 ) 6 . History Kidney and/or liver failure ( include transplant ) problem ( e.g. , cirrhosis ) ; current liver disease impairment . 7 . History current diagnosis hepatitis . 8 . Liver function test 20 % outside normal range . 9 . Allergies study medication , tolcapone ( Tasmar ) . 10 . History severe , uncontrolled muscle movement ( e.g. , uncontrolled jerking , twitch ) certain severe muscle problem ( rhabdomyolysis ) . 11 . Experience dizziness lightheadedness upon stand regular basis ( i.e. , daily ) . Genetic Profile 1 . Individuals heterozygous genotype ( val/met ) catecholmethyl transferase ( COMT ) gene . ( Note : small pilot study compare effect Tolcapone cognitive performance val/val ( n=8 ) individual . ) Future research do center plan include carry val/met genotype . 2 . Individuals homozygous genotype , met/met , COMT gene . As December 2008 , study accrue 8 met/met participant . To balance genotype group , study recruit equal number participant val/val genotype COMT gene include participant homozygous , met/met genotype . Future research do center plan include carry met/met genotype . 3 . NonEuropean ancestry determine self report initial telephone screening ; expect ethnic difference allele frequency COMT ; therefore , December 2008 , reduce ethnic admixture could bias genetic analysis small sample , study restrict individual European ancestry . All participant nonEuropean ancestry refer study center . General Exclusion 1 . Any medical condition concomitant medication could compromise participant safety treatment , determine Principal Investigator and/or Study Physician . 2 . Inability provide inform consent complete study task determine Principal Investigator and/or Study Physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Smoking , Abstinence</keyword>
</DOC>